The novel coronavirus, SARS-CoV2 has affected over 28 million people in the United States as of February 2021.1 Limited literature describe the effects of SARS-CoV2 infection on pediatric patients who have received hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality in post-transplant patients. Although the pathophysiology of GVHD is well-described; identification of risk factors and successful treatment of severe, refractory GVHD is still wanting. We present two pediatric cases of acute GVHD exacerbation after SARS-CoV2 infection to recognize a potential risk factor for development of GVHD in pediatric HSCT recipients.